Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.

MLA

Tandon, Ruchi, et al. “Dual Epidermal Growth Factor Receptor (EGFR)/Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor: A Novel Approach for Overcoming Resistance in Anticancer Treatment.” European Journal of Pharmacology, vol. 667, no. 1–3, Sept. 2011, pp. 56–65. EBSCOhost, https://doi.org/10.1016/j.ejphar.2011.04.066.

APA

Tandon, R., Kapoor, S., Vali, S., Senthil, V., Nithya, D., Venkataramanan, R., Sharma, A., Talwadkar, A., Ray, A., Bhatnagar, P. K., & Dastidar, S. G. (2011). Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment. European Journal of Pharmacology, 667(1–3), 56–65. https://doi.org/10.1016/j.ejphar.2011.04.066

Chicago

Tandon, Ruchi, Shweta Kapoor, Shireen Vali, V Senthil, D Nithya, R Venkataramanan, Ashish Sharma, et al. 2011. “Dual Epidermal Growth Factor Receptor (EGFR)/Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor: A Novel Approach for Overcoming Resistance in Anticancer Treatment.” European Journal of Pharmacology 667 (1–3): 56–65. doi:10.1016/j.ejphar.2011.04.066.